2008 / 02

Established.

2008 / 07

 

R&D personnel from Orient Europharma(OEP) moved to Orient Pharma(OP) and continued the pharmaceutical research.

2008 / 10

Cash capital increased, with the actual receipt capital to be $900,000,000 NTD.

2009 / 05

 

 

Subsidiary Orient Pharma (Samoa) Co., Ltd. signed a contract with Summit Corporation Plc for collaborating research and development of a new formulation for treating sialorrhea (excessive drooling) for patients with Parkinson’s disease.

2009 / 08

 

Signed contract with Durect Corporation for development and manufacturing of a new drug for treating attention deficit hyperactivity disorder.

2009 / 09

 

 

Approved to be a biotech and new pharmaceutical company by Ministry of Economic Affairs and can apply for encouragement of investment according to “Biotech and New Pharmaceutical Development Act”.

2010 / 12

 

Applied for IND of a new drug for treating sialorrhoea (excessive drooling) in Parkinson’s disease to FDA and was approved to start clinical trials.

2011 / 03

 

Being approved by FDA to start phase II clinical trial of the new drug for treating sialorrhoea in Parkinson’s disease.

2011 / 05

 

 

Signed the contract with Elan Corporation, plc to manufacture its brandname pharmarceutical products, and authorized the companies the exclusive rights in North America to sell pharmaceutical products manufactured by OP.

2011 / 05

 

 

 

Self-developed sustained release oral tablets of two generics with international niche market for treating benign prostatic hyperplasia were approved by Ministry of Economic Affairs as an Industrial Technology Development Program and gained government subsidy.

2011 / 07

The Yunlin plant received the approval for PIC/S GMP from Taiwan FDA.

2011 / 08

Applied for IPO.

2012 / 04

The Yunlin plant received “Accreditation Certificate of Foreign Drug Manufacturer” from Japan Ministry of Health, Laboar, and Welfare (MHLW)

2012 / 06

Listed to emerging market in Taiwan

2013 / 04

The Yunlin plant passed the cGMP inspection by US FDA.

2014 / 10

Muscle relaxant gained product approval by US FDA.

2014 / 12

Signed license and supply agreement with Beijing Tide Pharmaceutical Co., Ltd

2015 / 02

Anti-diabetes agent gained product approval by US FDA.

2015 / 07

Recognized as Top 30 biotech companies in Taiwan by Institute for Biotechnology and Medicine Industry.

2015 / 10

Signed development and license agreement with Supernus Pharmaceutical, Inc. for a CNS product.

2015 / 12

ER capsule for treating ADHD and new drug for treating Sialorrhoea won the Bronze Medal of '2015 Pharmaceutical Technology Research & Development Prize" by Ministry of Health and Welfare and Ministry of Economic Affairs.

2017 / 02

Anti-hyperlipidemia agent gained product approval by US FDA.